Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tissue factor pathway inhibitor gene disruption

G J Broze1

  • 1Division of Hematology, Washington University School of Medicine, Barnes-Jewish Hospital, St Louis, MO 63110, USA. gbroze@im.wustl.edu

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|November 18, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Evidence of clinically significant extravascular stores of factor IX.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Protein Z, protein Z-dependent protease inhibitor (serpinA10), and the acute-phase response.

Journal of thrombosis and haemostasis : JTH·2012
Same author

The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Tissue factor pathway inhibitor endocytosis.

Trends in cardiovascular medicine·2011
Same journal

Pampiniform venous plexus thrombosis in a 37 years-old male patient with severe thrombocytosis: a multifactorial aetiology.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

PROS1 Cys475Tyr mutation associated with a type III protein S deficiency pattern.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Dynamic microclot profiling: thromboelastography advances precision management in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Genetic characterization of Glanzmann thrombasthenia: insights from novel igta2b mutations in a Tunisian patient cohort.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

Uterine fibroids as an underrecognized risk factor for venous thromboembolism: a narrative review.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
Same journal

SEER sonorheometry enhances fibrinolysis detection during liver transplantation with heparin.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2026
See all related articles

Gene targeting revealed that tissue factor pathway inhibitor (TFPI) is crucial for embryonic survival. Disruption of TFPI's first Kunitz domain causes embryonic lethality due to severe hemorrhage, highlighting TFPI's essential role in regulating coagulation.

Area of Science:

  • Hemostasis and Thrombosis
  • Molecular Biology
  • Developmental Biology

Background:

  • Tissue factor pathway inhibitor (TFPI) is a key regulator of coagulation initiation.
  • TFPI inhibits the tissue factor (TF)-FVIIa catalytic complex via its Kunitz domains.
  • The first Kunitz domain of TFPI specifically targets FVIIa within the TF-FVIIa complex.

Purpose of the Study:

  • To investigate the physiological role of TFPI in embryonic development.
  • To determine the consequences of disrupting the first Kunitz domain of TFPI.

Main Methods:

  • Gene targeting was employed to disrupt exon 4 of the mouse TFPI gene, specifically affecting the first Kunitz domain.
  • Analysis of TFPI(K1)(-/-) mice for embryonic lethality, hemorrhage, and coagulation abnormalities.

Related Experiment Videos

  • Functional assays measured plasma TFPI activity in heterozygous TFPI(K1)(+/-) mice.

    • Main Results:

    • TFPI(K1)(-/-) mice exhibit embryonic lethality between days 9.5 and 11.5, characterized by yolk sac hemorrhage.
    • Surviving TFPI(K1)(-/-) embryos show widespread hemorrhage, particularly in the CNS and tail, and do not reach the neonatal period.
    • Evidence of fibrin(ogen) and intravascular thrombi suggests unregulated TF-FVIIa activity and consumptive coagulopathy.

    Conclusions:

    • The first Kunitz domain of TFPI is essential for preventing embryonic lethality.
    • TFPI plays a critical role in regulating coagulation during embryonic development to prevent fatal hemorrhage.
    • Human TFPI deficiency may result in similar embryonic developmental defects.